Hao Yuan Medicine: Holding subsidiary Chongqing Hao Yuan passed EU QP audit.

HaoYuan Pharmaceutical announced that its holding subsidiary, Chongqing HaoYuan Biopharmaceutical Co., Ltd., recently successfully passed the EU Qualified Person (QP) audit and obtained a compliance audit report issued by the QP. The audit covered aspects such as quality management, production management, plant equipment facilities, material systems, packaging and labeling systems, reviewing key areas such as aseptic assurance, computerized systems, data integrity, quality management, material management, etc. Chongqing HaoYuan has established an organizational structure, personnel configuration, facilities, procedures, etc. that comply with EU GMP requirements. Passing the QP audit indicates that Chongqing HaoYuan's quality management system and production capacity have reached EU GMP standards, ensuring the high-quality research and production of biopharmaceuticals such as monoclonal antibodies, bispecific antibodies, multi-specific antibodies, recombinant proteins, and antibody-drug conjugates, laying the foundation for expanding domestic and international markets. Passing the QP audit this time will not have a significant impact on the company's current performance.